Announcing Verum: a platform to reshape healthcare delivery

Nov 6, 2018 | Newsroom

November 06, 2018 – Breakthrough innovation specialist Cambridge Consultants has designed ‘Verum’, a digital health platform that will reshape the way healthcare is delivered. The platform remotely monitors patients and provides machine learning-driven predictions around conditions or disease states. Verum’s initial test application focuses on clinical trials, where huge efficiencies can be achieved by identifying and mitigating the effect of patient stress on trial outcomes.

Stress is an underlying cause of behavioural and disease states and yet it is poorly characterized, leading to badly controlled clinical trials with average drop-out rates at 30%[1]. For proof of concept, Cambridge Consultants designed a system to measure and monitor a participant’s stress levels during trials. Developed in consultation with clinical psychiatrists and neuroscientists, Verum harnesses the power of biometric data, primarily voice and electromyography (EMG), and machine learning to better understand outcomes and increase the likelihood of clinical success. This machine learning-driven system can provide deeper insight on participants during trials through real-time triggers and alerts, enabling clinicians, nurses and trial co-ordinators to mitigate the effect of stress on compliance, investigate stress as a confounding factor and inform better adaptive trial design through continuous data streams. With the average cost of a Phase 2 clinical trial ranging from $7 million to $19.6 million[2] and 80% of all clinical trials failing to reach completion[3] it’s clear that increased efficiency has the potential to deliver very significant savings.

Verum comprises sensors integrated into a wearable, a data collection app and a widget for healthcare dashboards that augments existing data with patient-specific predictions and alerts, for unprecedented clinical insight. Verum’s ability to provide rich, contextualized biometric information at both population and patient level has the potential to revolutionize precision medicine, post-market surveillance and drug development.

Verum works by enabling clinicians, nurses and trial co-ordinators to access biometric and behavioural data from continuously monitored patients, gaining valuable context around a specific condition. This is achieved by applying a machine learning algorithm to measure patient data, producing a single numerical estimator of a patient’s stress levels at any stage of the trial.

Commenting on Verum, Jaquie Finn, Head of Digital Health at Cambridge Consultants, said: “The rising cost of clinical trials, combined with the commercial risks of failure, mean it’s vital we’re able to harness the power of AI and continuous patient monitoring to mitigate the impact of stress on clinical trial outcomes. Verum informs better adaptive trial design through bigger, real-time contextualized data sets and will mark a step-change in the efficiency of clinical trials.”

Potential future applications of Verum include the diagnosis of neurological conditions, the post market surveillance of drugs, the development of closed loop therapeutics, rehabilitation and remote patient monitoring. Within the consumer space, Verum can enable consumer brands to gain measured, quantitative insights into the use of products during trials. This could accelerate the product development process and provide new insights to spark innovation.

Notes to editors

About Cambridge Consultants and Capgemini

About Cambridge Consultants
As the deep tech powerhouse of Capgemini, Cambridge Consultants (CC), is a global team of 800 bright, talented people. We are united by the ambition to turn brilliant ideas into technologies, products and services that have never been seen before. And which will transform business, society and the planet. Deep tech is a mindset; a bold strategy that harnesses radical science and engineering to achieve things no-one else can. It enables our clients to gain unassailable commercial advantage from defendable technology that they own. We are trusted by some of the world’s biggest brands and most ambitious start-ups to realise their critical technology-based aspirations – and we’ve been doing it for 60 years. Cambridge Consultants is part of Capgemini Invent.

About Capgemini
Capgemini is a global business and technology transformation partner, helping organisations to accelerate their dual transition to a digital and sustainable world, while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, Capgemini is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fueled by its market leading capabilities in AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2023 global revenues of €22.5 billion

Get The Future You Want

Visit us at www.capgemini.com

Recent announcements

Deep tech

Are you curious about new technologies, and how they can lead to long-term sustainable value?

We think creatively at the intersection of business and technology, inventing solutions to redefine what you do.

Industries

You need a partner with intimate knowledge of your industry and proven experience of delivering value from deep tech breakthroughs.

Discover more about the work we do in your sector and how we can create real commercial advantage for you.

Insights

Take a look at the latest insights, ideas and perspectives from CC.

Explore a cross-section of up-to-date content on the deep tech trends shaping the future of business and society.

Careers

Are you looking for an opportunity for your abilities to be recognised, and make a real difference?

Whether you are just starting out or you’re an experienced professional, we would love to hear from you.